Freenome and Perceptive Capital Solutions Corp have entered into a definitive business combination agreement to create a publicly listed company.
The combined company is expected to be listed on Nasdaq under the ticker symbol FRNM.
The business combination is set to be completed in the first half of 2026 with leading institutional investors committing $240 million through a private investment in public equity.
PIPE Investment
Institutional investors committed $240 million through a private investment in public equity (PIPE) at $10.00 per share.
Listing on Nasdaq
The combined company is expected to be listed on Nasdaq under the ticker symbol FRNM.
Strategic Partnerships
Freenome has secured commercialization partnerships and aims to launch multiple tests in 2026.
- The transaction is set to provide the combined company with approximately $330 million in net proceeds for business expansion and acceleration.
- The partnership between Freenome and PCSC aims to revolutionize blood-based cancer detection through advanced technology and strategic investments.
The collaboration between Freenome and Perceptive Capital Solutions Corp signifies a pivotal moment for blood-based cancer screening and paves the way for personalized multi-cancer detection.